Exploring Model Systems in Amyotrophic Lateral Sclerosis Research

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a devastating neurodegenerative disorder characterized by the progressive degeneration of human motor neurons in the brain and spinal cord. Despite significant advancements in understanding ALS pathology, the lack of effective treatments remains a significant challenge.

Fig. 1 ALS pathophysiology, genetic causes and risk factors.¹

Creative Biolabs delves into the intricate world of ALS research, focusing on the indispensable role of in vitro and in vivo models in elucidating disease mechanisms, screening potential therapeutics, and advancing drug discovery efforts. We will explore the strengths and limitations of various model systems, shedding light on their contributions to ALS research and highlighting recent innovations and emerging trends.

As a partner, we offer the following related services to help accelerate the progress of your ALS program.

The Importance of Model Systems in ALS Research

ALS is a devastating neurological disorder characterized by the progressive degeneration of motor neurons, leading to muscle weakness, atrophy, and eventually death. Model systems serve as indispensable platforms for investigating the intricate mechanisms underlying ALS pathology.

• They allow researchers to dissect molecular pathways, study disease progression, and screen potential therapeutics in a controlled environment.
• These models provide valuable insights into the heterogeneity of ALS, which manifests clinically with varying degrees of motor neuron degeneration and extramotor involvement.
• By faithfully mimicking aspects of ALS pathology, model systems enable researchers to interrogate disease mechanisms across different biological scales, from individual cells to entire organisms.

Researchers rely heavily on model systems to simulate the disease condition in a controlled environment, paving the way for an understanding of the disease's pathogenesis and the progression, and potentially devising targeted treatments. Thus, model systems indubitably form the backbone of ALS research, providing insights into disease mechanisms and facilitating the testing of intervention strategies.

A number of cell models are important tools commonly used in ASL research. You can browse the table below to see a list of our recommended products.

In Vitro Assays For ALS Models

[Brochure]

Neuros Celll Product Panel

View

[Brochure]

In Vitro Service

View

In vitro neuronal models have been a gold standard in ALS research, offering a reductionist approach to studying the intricacies of cellular and molecular processes associated with motor neuron degeneration. The use of animal cells, including primary neuron cultures, stem-cell-derived neurons, and cell lines facilitate a detailed exploration into the course of motor neuron diseases.

By recapitulating essential aspects of the molecular pathology of ALS, these in vitro assays provide an invaluable platform for studying gene expression, protein aggregation, intracellular trafficking, cellular metabolism, and neuronal and non-neuronal cell interactions.

In Vivo Models for ALS

In vivo models remain indispensable tools for ALS research, offering the complexity of a living organism and the ability to assess disease progression in a physiological context. Several genetically-engineered models of ALS, typically harbouring mutations in genes known to cause human ALS, such as

• SOD1
• TDP-43
• FUS
• C9ORF72

These models recapitulate key features of ALS pathology, including protein aggregation, axonal degeneration, and gliosis, providing valuable insights into disease progression and potential therapeutic targets.

Moreover, advances in genome editing technologies, such as CRISPR-Cas9, have facilitated the generation of precise genetic modifications, allowing for the development of new ALS models with enhanced fidelity to human disease.

Future Directions for Model Development

The future of model development for ALS research holds promise, with the increasing sophistication of model systems.

• One promising approach is the development of organoid models derived from patient iPSCs, which recapitulate the cellular diversity and architecture of the human central nervous system.
  • These three-dimensional cultures allow for the study of cell-cell interactions and disease propagation in a more physiologically relevant context.
  • Furthermore, the integration of multi-omics technologies, such as transcriptomics, proteomics, and metabolomics, promises to provide a comprehensive understanding of ALS pathogenesis and identify novel therapeutic targets.
• Innovative approaches to in vivo modeling are emerging, such as the use of zebrafish and Drosophila, providing lower-cost, high-throughput platforms for disease modeling and drug screening. The continued refinement of animal models, including the generation of non-human primate models of ALS, holds promise for bridging the gap between preclinical research and clinical translation.

From in vitro assays to in vivo mouse models, each system offers unique insights into disease mechanisms and therapeutic targets. By harnessing the power of diverse model systems and embracing emerging technologies, researchers can accelerate progress towards a future where ALS is no longer a fatal diagnosis.

Creative Biolabs, with its roots grounded in a deep understanding of ALS and the molecular processes involved, leverages both in vitro and in vivo models. Our insightful approach equips us to forge solutions that unravel the disease's circuitry.

References

1. Mead, Richard J., et al. "Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation." Nature Reviews Drug Discovery 22.3 (2023): 185-212.
2. Zhu, Longhong, et al. "Pathological insights from amyotrophic lateral sclerosis animal models: comparisons, limitations, and challenges." Translational Neurodegeneration 12.1 (2023): 46.

Related Scientific Resources

Amyotrophic Lateral Sclerosis (ALS)

Genome-Wide Identification of the Genetic Basis of Amyotrophic Lateral Sclerosis